Attorneys spent a second day in court Monday arguing over whether Apotex’ generic version of the blockbuster blood thinner Plavix should be allowed on the market.
A federal judge has ruled that a landmark Supreme Court decision involving eBay only relates to permanent injunctions and not preliminary ones.
Timeline Inc. announced Monday that it has terminated a limited license with Microsoft Corp. for use of its patents with the software giant’s SQL Servers, and has asked a federal court to add Microsoft to a patent infringement lawsuit.
DexCom Inc. revealed Friday that it received a favorable ruling in a patent infringement dispute with rival Abbott Diabetes Care Inc. over technology related to glucose monitors used by diabetics.
In another victory for brand name drug companies, a federal jury has rejected Dutch generics maker Synthon IP Inc.’s claim that Pfizer Inc.’s blockbuster blood pressure drug Norvasc violates its intellectual property.
A tiny Houston-based company has dragged five corporate giants into federal court in Texas, claiming they infringed on a patent related to miniscule microchips used to keep track of inventory.
The U.S. Courts of Appeals for the Federal Circuit Friday blocked a temporary injunction that would have prevented Echostar Communication Corp. from selling some of its digitial video recorders and stopped the service of about 4 million DVRs within 30 days.
Class action suits are popping up, following the U.S. Federal Trade Commission’s decision that technology-licensing company Rambus Inc. violated antitrust laws and deceived a group responsible for establishing industry-wide standards for memory-chip equipment.
In its ongoing battle to patent its cancer treatment Gleevec in India, Novartis AG has lashed out not only at the rejection of its patent application earlier this year, but at a key section of India’s recently enacted patent laws.
Canadian generic drug maker Apotex has accused Bristol-Myers of engaging in illegal secret side deals that led to a Department of Justice investigation into a Plavix settlement agreement.
Magma Design Automation Inc. got a piece of good news when the U.S. Patent and Trademark Office rejected all 15 claims in one of three patents at issue in the suit between Magma and rival Synopsys Inc.
A federal judge has overturned a $46.58 million jury verdict in a patent infringement case from 2001 over aircraft power unit systems.
DeepNines Inc., a network security solutions company, is suing rival McAfee Inc. for patent infringement in an attempt to permanently stop McAfee from selling a network security device.
Swiping back in the battle over Pfizer Inc.’s Lipitor, Indian drug maker Ranbaxy Laboratories Ltd. on Wednesday asked a U.S. appeals court to reconsider part of a ruling that would block a generic version of the cholesterol medicine from hitting the market until 2010.
The first of thousands of personal injury lawsuits against Wyeth over the company’s hormone therapy drugs, which were used to treat the symptoms of menopause, is slated to begin on Monday.
In another electrifying win for the company, Symbol Technologies Inc. put the finishing touches on its settlement with Global Technology Systems over an intellectual property dispute relating to GTS’ Honeywell batteries.
Signing on as the new partner in Dechert LLP’s Austin, Tex. office was a homecoming of sorts for Steven R. Daniels—and not just because he recently returned from South Korea.
Weeks after protestors rallied against British drug maker GlaxoSmithKline’s efforts to patent an anti-retroviral in Thailand, the World Bank warned in a report Wednesday that the country must decide whether to shell out market prices for patented drugs as a rising number of Thais living with HIV/AIDS are forced to turn to so-called second-line drugs.
Before coming to Fish & Richardson PC earlier this month, 67-year-old IP lawyer Jonathan A. Marshall briefly considered retirement. His firm, Weil Gotshal & Manges, required its attorneys to step down once they hit 68, an age at which not many people are thinking of starting over in a new position.
In an attempt to cope with Apotex Inc.’s recent launch of generic Plavix, Bristol-Myers Squibb Co. and Sanofi-Aventis SA are offering the buyers of Plavix prices below the price of the generic version.